| 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2024-021 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 上海神奇制药投资管理股份有限公司 关于股东股票质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公 司"） 的股东贵州迈吉斯投资管理有限公司（以下简称"迈吉斯"）持有公司 88,001,946 股，占公司总股本 16.48%；本次质押 1,300,000 股，累计质押股份 65,069,000 股，占公司总股份数 12.18%，占其持有公司股份 73.94%。 公司控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"） 及其控股公司迈吉斯合计持有公司 178,663,566 股，占公司总股本 33.45%；累 计质押股份 110,369,000 股，占公司总股份数 20.67%， ...

类 型：股份有限公司（外商投资、上市） 法定代表人：ZHANG TAO TAO 注册资本：人民币 53407.1628 万 证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2024-020 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 关于完成工商变更登记并取得营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海神奇制药投资管理股份有限公司（以下简称"公司"） 根据《外商 投资法》规定和《市场监管总局关于贯彻落实《外商投资法》做好外商投资企业登 记注册工作的通知》（国市监注[2019]247 号）的要求，向上海市市场监督管理局申 请，办理完成了工商变更登记手续，并于 2024 年 7 月 31 日取得了上海市市场监督 管理局换发的营业执照。 此次变更，公司类型由"股份有限公司（中外合资、上市）"变更为"股份有限 公司（外商投资、上市）"。变更后公司具体工商登记内容如下： 公司名称：上海神奇制药投资管理股份有限公司 社会统一信用代码： 91310000 ...

900904 | 神奇Ｂ股 证券代码：600613 证券简称：神奇制药 公告编号：2024-019 上海神奇制药投资管理股份有限公司 2023 年年度权益 分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.10 元，B 股每股现金红利 0.014071 美元 相关日期 | Ａ股 | 2024/6/17 | － | 2024/6/18 | 2024/6/18 | | --- | --- | --- | --- | --- | | 股份类别 Ｂ股 | 股权登记日 2024/6/21 | 最后交易日 2024/6/17 | 除权（息）日 | 现金红利发放日 2024/7/3 | | Ａ股 | 2024/6/17 | － | 2024/6/18 | 2024/6/18 | | --- | --- | --- | --- | --- | | 股份类别 Ｂ股 | 股权登记日 2024/6/21 | 最后交易日 2024/6/17 | 除权（息）日 | 现金红利发放日 202 ...

| 证券代码：A | 股 600613 股票简称：A 股 神奇制药 编号：2024-018 | | --- | --- | | B | 股 900904 B 股 神奇 B 股 | 上海神奇制药投资管理股份有限公司 关于控股股东提前购回部分股票解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海神奇制药投资管理股份有限公司（以下简称"公司"或"本公司"） 的控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"）持有公司 90,661,620 股，占公司总股本 16.98%；办理了股票质押式回购交易提前购回业 务，解除质押 9,000,000 股；剩余累计质押股份 45,300,000 股，占公司总股份 数 8.48%，占其持有公司股份 49.97%。 神奇控股及其控股公司贵州迈吉斯投资管理有限公司（以下简称"迈吉 斯"）合计持有公司 178,663,566 股，占公司总股本 33.45%；累计质押股份 109,069,000 股，占公司总股份数 20.42%，占其合计持有公司股份 61 ...

重要内容提示： 本次会议是否有否决议案：无 证券代码：600613 证券简称：神奇制药 公告编号：2024-017 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | | 10 | | --- | --- | --- | | 其中：A | 股股东人数 | 10 | | 境内上市外资股股东人数（B | 股） | 0 | | 2、出席会议的股东所持有表决权的股份总数（股） | | 178,706,372 | | 其中：A | 股股东持有股份总数 | 178,706,372 | | 境内上市外资股股东持有股份总数(B | 股) | 0 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | 33.4611 | | 份总数的比例（%） | | | | 其中：A | 股股东持股占股份总数的比例（%） | 33.4611 | | 境内上市外资股股东持股占股份总数的比例（ ...

北京德恒（贵阳）律师事务所 关于上海神奇制药投资管理股份有限公司 2023 年年度股东大会的 法律意见 北京德恒（贵阳）律师事务所 关于上海神奇制药投资管理股份有限公司 2023 年年度股东大会的 法律意见 德恒【38F20240039】号 致：上海神奇制药投资管理股份有限公司 北京德恒（贵阳）律师事务所（以下简称本所）受上海神奇制药投资管理股 份有限公司（以下简称"公司"）的委托，指派吉明律师、徐宝峰律师（以下简称"本 所律师"）出席公司 2023 年年度股东大会（以下简称"本次股东大会"），并对本 次股东大会的合法性进行见证并出具法律意见。 贵阳市高新区长岭南路茅台国际商务中心 C 栋 27 层 电话：0851-88259188 邮编：550081 北京德恒（贵阳）律师事务所 上海神奇制药投资管理股份有限公司 2023 年年度股东大会法律意见 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规 则（2022 年修订）》，以及《上海神奇制药投资管理股份有限公司公司章程》（以 下简称"《公司章程》"）等有关法律法规和规 ...

上海神奇制药投资管理股份有限公司 内部控制审计报告 2023 年 12 月 31 日 内部控制审计报告 信会师报字[2024]第 ZA12362 号 上海神奇制药投资管理股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了上海神奇制药投资管理股份有限公司（以下简称 神奇制药）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是神奇制药董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内部控制审计报告 第 1 页 四．财务报告内部控制审计意见 我们认为 ...

公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2023 年度内部控制评价报告 上海神奇制药投资管理股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 574,528,830.84, representing a decrease of 1.42% compared to the same period last year[7] - Net profit attributable to shareholders was CNY 23,944,713.73, an increase of 0.65% year-on-year[7] - Operating profit for Q1 2024 was CNY 31,746,214.60, a decrease of 3.1% compared to CNY 32,746,831.05 in Q1 2023[22] - The net profit for Q1 2024 was CNY 25,123,136.63, an increase of 7.57% compared to CNY 23,351,102.30 in Q1 2023[23] - The company reported a total comprehensive income of CNY 25,346,836.31 for Q1 2024, compared to CNY 25,338,281.91 in Q1 2023[23] Cash Flow - The net cash flow from operating activities increased significantly by 82.28%, amounting to CNY 42,806,771.33, due to improved collection of receivables and better expense management[7] - The net cash flow from operating activities increased to CNY 42,806,771.33, compared to CNY 23,483,555.88 in Q1 2023, representing an increase of 82.5%[24] - The net cash flow from financing activities improved to CNY 1,092,398.13, compared to a negative CNY 8,231,985.32 in Q1 2023[25] - The cash outflow from investing activities was CNY 2,250,231.46, a decrease from CNY 23,583,667.45 in the previous year[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,292,343,075.29, reflecting a slight increase of 0.40% from the end of the previous year[7] - Total assets as of March 31, 2024, were CNY 3,292,343,075.29, slightly up from CNY 3,279,335,678.82 at the end of 2023[18] - Total liabilities decreased to CNY 876,639,733.31 from CNY 888,769,635.45 at the end of 2023, a reduction of 1.0%[18] - The company's retained earnings increased to CNY 762,654,723.15, up from CNY 738,919,547.12 at the end of 2023, reflecting a growth of 3.2%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 61,918[12] - The largest shareholder, Guizhou Magic Holdings, held 22.59% of the shares, with 120,661,620 shares pledged[12] Research and Development - The company reported a decrease in research and development expenses by 53.24%, primarily due to reduced investment in manufacturing R&D during the reporting period[9] - Research and development expenses for Q1 2024 were CNY 8,960,100.75, significantly down 53.2% from CNY 19,160,727.57 in Q1 2023[22] Other Financial Metrics - The weighted average return on equity was 1.01%, a decrease of 0.01 percentage points compared to the previous year[7] - The company reported a total of CNY 172,851.60 in non-recurring gains and losses for the period[9] - Total operating costs for Q1 2024 were CNY 543,620,372.68, down 1.3% from CNY 551,049,481.13 in Q1 2023[22] - Cash and cash equivalents increased to CNY 756,928,121.90 as of March 31, 2024, up from CNY 715,276,992.64 at the end of 2023, representing a growth of 5.8%[16] - Accounts receivable rose to CNY 398,328,039.01, an increase of 1.5% from CNY 393,179,805.42 at the end of 2023[16] - Inventory decreased to CNY 223,443,090.05, down 7.9% from CNY 242,859,435.85 at the end of 2023[16] - The company experienced a decrease in other comprehensive income, with a net amount of CNY 223,699.68 in Q1 2024, down from CNY 1,987,179.61 in Q1 2023[23] - The total operating cash inflow was CNY 512,993,663.80, while the total operating cash outflow was CNY 470,186,892.47, resulting in a positive net cash flow from operations[24] - The basic and diluted earnings per share remained stable at CNY 0.04 for both Q1 2024 and Q1 2023[23]

Financial Performance - The company's operating revenue for 2023 was CNY 2,340,945,518, a decrease of 2% compared to CNY 2,388,617,678 in 2022[21]. - Net profit attributable to shareholders increased by 17.41% to CNY 57,000,674.55 from CNY 48,548,121.74 in the previous year[23]. - Cash flow from operating activities decreased by 32.47% to CNY 215,590,355.95, down from CNY 319,232,403.36 in 2022[23]. - Basic and diluted earnings per share rose by 22.22% to CNY 0.11, compared to CNY 0.09 in 2022[22]. - The weighted average return on equity increased by 0.35 percentage points to 2.42% from 2.07% in the previous year[22]. - Total assets decreased by 3.15% to CNY 3,279,335,678.82 from CNY 3,386,135,812.03 in 2022[21]. - The net asset attributable to shareholders increased slightly by 0.36% to CNY 2,335,387,196.13 from CNY 2,327,112,527.12 in 2022[21]. - The net profit after deducting non-recurring gains and losses increased by 0.84% to CNY 49,103,973.11[23]. - The total profit for 2023 was 83.41 million yuan, representing a year-on-year increase of 31.92%[32]. - The company reported a significant decline in cash flow due to reduced sales revenue and slower cash collection[23]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.8 RMB based on a total share capital of 534,071,628 shares as of December 31, 2023[5]. - The company distributed a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.80 RMB, which represents 93.70% of the net profit attributable to ordinary shareholders in the consolidated financial statements[193]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[4]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with more than half of the directors being unable to ensure the authenticity and completeness of the annual report[9]. - The company has confirmed that the financial report is true, accurate, and complete as stated by the responsible persons[5]. - The company has not disclosed any significant changes in its registered address or office location[16]. - The company has conducted self-inspections regarding fund occupation and illegal guarantees, confirming compliance with regulations and no violations found[159]. - The internal control audit report received a standard unqualified opinion[197]. - There were no significant deficiencies in internal control during the reporting period[197]. Risk Management - The company has detailed potential risks in the section discussing future development in the annual report[9]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements in the annual report[6]. - The company has established mechanisms for environmental protection[200]. - The company recognizes quality control risks stemming from complex production processes and has established measures to enhance quality management capabilities, including ongoing training and process monitoring[152]. - The company will enhance its internal control management system to improve operational efficiency and risk management capabilities[141]. Research and Development - Continuous investment in R&D led to multiple technological innovations and quality standard improvements, with some results achieving domestic leading levels[40]. - The company is actively working on enhancing the quality standards of traditional Chinese medicine and ethnic medicine, aiming to include more varieties in the Chinese Pharmacopoeia[41]. - The company has made progress in the technical enhancement and quality standard improvement of potential products, opening new sales growth points[42]. - The company has increased its R&D investment in traditional Chinese medicine, achieving multiple technological innovations and quality standard improvements, with some results already applied in production and pending national patent applications[97]. - The company’s R&D projects include the development of new indications for existing drugs, with ongoing basic research in various therapeutic areas[110]. - The company has a research and development team of 203 personnel, with over 56% holding bachelor's degrees or higher, focusing on various pharmaceutical disciplines[107]. - The company applied for 5 invention patents and 9 utility model patents in 2023, reinforcing its commitment to intellectual property protection[70]. - The total R&D expenditure for the company was RMB 90,940.92 million, which is 38.85% of its revenue, a decrease of 3.13 percentage points year-on-year[120]. Market and Industry Trends - The pharmaceutical industry in China experienced a decline in overall growth, with the industrial added value of large-scale pharmaceutical enterprises approximately 1.3 trillion yuan, a year-on-year decrease of 5.2%[51]. - The revenue of pharmaceutical industrial enterprises reached 2.95525 trillion yuan, down 4% year-on-year, while profits fell to 412.72 billion yuan, a decrease of 16.2%[51]. - Different sub-industries showed varied performance, with traditional Chinese medicine (TCM) and Chinese patent medicines maintaining positive growth rates of 14.6% and 6.5% respectively, while chemical raw materials and biological products saw significant declines[52]. - The overall pharmaceutical market in China is projected to grow at a compound annual growth rate (CAGR) of 9.6% from 2020 to 2025[130]. - The company anticipates a decline in revenue and profit due to ongoing policy changes in the pharmaceutical industry, with a focus on adapting to these changes to maintain profitability[143]. Corporate Governance - The company has a governance structure that complies with the latest regulations, ensuring effective operation and protection of shareholder rights, particularly for minority shareholders[156]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement for independent oversight[157]. - The company has established transparent performance evaluation and incentive mechanisms for senior management to promote long-term stability and development[158]. - The company has maintained a stable governance structure with independent directors and a supervisory board that operates independently[160]. - The company has a structured approach to evaluating and compensating its directors and senior management[175]. Environmental Responsibility - The company has implemented a strict environmental responsibility system, including an "environmental veto" policy and increased investment in environmental protection measures[150]. - The company invested 2.6165 million yuan in environmental protection during the reporting period[200]. - There were no administrative penalties related to environmental issues during the reporting period[200]. - The company adheres to various environmental discharge standards for air and water pollutants[200]. Strategic Initiatives - The company implemented a strategy of "focus, optimization, and integration" to enhance operational efficiency and adapt to industry changes[36]. - The company aims to enhance its brand value and market influence, having received multiple awards in 2023, including "Top 100 Chinese Traditional Medicine Enterprises" and "Outstanding Brand Enterprise in Chinese Medicine" for its loquat cough series products[46][47]. - The company plans to focus on innovation and quality, aiming to enhance brand value and market influence while expanding into various business areas including manufacturing and e-commerce[133]. - The company will enhance R&D and innovation capabilities, focusing on core products in oncology and cardiovascular areas, utilizing both "internal growth and external expansion" strategies for new vitality[134]. - The company aims to develop a series of single products with over 100 million in sales, focusing on traditional Chinese medicine as a new profit growth point[140].